Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Coherus Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Coherus Oncology, Inc.’s stock price such as:

• Coherus Oncology, Inc.’s current stock price and volume
• Why Coherus Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for CHRS from analysts
• CHRS’s stock price momentum as measured by its relative strength

About Coherus Oncology, Inc. (CHRS)

Before we jump into Coherus Oncology, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Want to learn more about Coherus Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Coherus Oncology, Inc..

Coherus Oncology, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Coherus Oncology, Inc.’s stock price was $1.410.

Coherus Oncology, Inc. is down 4.08% from its previous closing price of $1.470.

During the last market session, Coherus Oncology, Inc.’s stock traded between $1.400 and $1.480. Currently, there are approximately 136.40 million shares outstanding for Coherus Oncology, Inc..

Coherus Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Coherus Oncology, Inc. Stock Price History

Coherus Oncology, Inc.’s (CHRS) price is currently up 0.71% so far this month.

During the month of July, Coherus Oncology, Inc.’s stock price has reached a high of $1.710 and a low of $1.360.

Over the last year, Coherus Oncology, Inc. has hit prices as high as $2.616 and as low as $0.810. Year to date, Coherus Oncology, Inc.’s stock is down 0.7%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Coherus Oncology, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 31, 2026,, no analysts have changed their rating of Coherus Oncology, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Coherus Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Coherus Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Coherus Oncology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Coherus Oncology, Inc. (CHRS) by visiting AAII Stock Evaluator.

Relative Price Strength of Coherus Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Coherus Oncology, Inc. has a weighted four-quarter relative price strength of 4.88%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Coherus Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Coherus Oncology, Inc. Stock Price: Bottom Line

As of July 31, 2026, Coherus Oncology, Inc.’s stock price is $1.410, which is down 4.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Coherus Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.